06628.HK
Transcenta Holding Limited
HKSE · Healthcare · Biotechnology · CN
HKD 0.98
+17.47%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 28.3M | 7.2M | 11.3M | 53.8M | 101.9M |
| Cost of Revenue | 10.0M | 48.0M | 7.3M | 39.5M | 82.0M |
| Gross Profit | 18.3M | (40.7M) | 4.0M | 14.4M | 19.9M |
| Operating Expenses | |||||
| R&D Expense | 115.6M | 99.2M | 192.1M | 382.0M | 349.8M |
| SG&A Expense | 51.3M | 55.6M | 30.6M | 49.9M | 49.1M |
| General & Admin Expense | — | — | 30.6M | 49.9M | 49.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | 25.6M | 69.0M | 63.4M |
| Total Operating Expenses | 166.9M | 154.8M | 248.3M | 500.9M | 462.2M |
| Cost and Expenses | 176.9M | 202.8M | 291.8M | 540.4M | 544.2M |
| Operating Income (EBIT) | (148.6M) | (195.5M) | (280.6M) | (486.5M) | (442.3M) |
| Non-Operating | |||||
| Interest Income | — | — | 8.9M | 15.6M | 24.0M |
| Interest Expense | — | 6.3M | 13.3M | 16.0M | 17.6M |
| Net Interest Income | (4.7M) | (6.3M) | (4.3M) | (459.0K) | 6.4M |
| Other Non-Op Income/Expense | (9.6M) | (3.2M) | (10.0M) | 23.7M | 35.4M |
| Non-Operating Income (excl Interest) | — | — | 33.0M | (39.7M) | (32.3M) |
| EBT (Pre-Tax Income) | (158.1M) | (198.7M) | (290.5M) | (462.8M) | (407.0M) |
| Income Tax Expense | 3.4M | (243.5K) | (250.0K) | (250.0K) | (246.0K) |
| Bottom Line | |||||
| Net Income | (161.3M) | (198.5M) | (290.3M) | (462.6M) | (406.7M) |
| Earnings from Cont. Ops | (161.3M) | (198.5M) | (290.3M) | (462.6M) | (406.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (161.3M) | (198.5M) | (290.3M) | (462.6M) | (406.7M) |
| Per Share | |||||
| Basic EPS | (HK$0.38) | (HK$0.48) | (HK$0.72) | (HK$1.14) | (HK$0.97) |
| Diluted EPS | (HK$0.38) | (HK$0.48) | (HK$0.72) | (HK$1.14) | (HK$0.94) |
| Revenue Per Share | HK$0.07 | HK$0.02 | HK$0.03 | HK$0.13 | HK$0.24 |
| Shares | |||||
| Basic Shares Outstanding | 426.4M | 414.2M | 404.8M | 407.0M | 417.9M |
| Diluted Shares Outstanding | 426.4M | 414.2M | 404.8M | 407.0M | 432.8M |
| Profitability Metrics | |||||
| EBITDA | (102.9M) | (153.1M) | (233.1M) | (393.0M) | (334.1M) |
| D&A | 45.7M | 42.4M | 47.4M | 53.8M | 55.3M |
| EBIT | (148.6M) | (195.5M) | (280.6M) | (446.8M) | (389.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026